Among EGFR-mutant lung cancer patients receiving EGFR-TKIs, shorter PFS was observed in SCC compared to adenocarcinoma, (median PFS (mPFS): 4.6 vs. 11 months, P<0.001, Figure 1B). Here, EGFR is linked to lung cancer.